Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

  title={Aclidinium bromide for the treatment of chronic obstructive pulmonary disease},
  author={Mario Cazzola and Clive P Page and Maria Gabriella Matera},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1205 - 1214}
Introduction: Although there are some challenges with current therapies, the growing evidence that tiotropium bromide is important in the maintenance treatment of chronic obstructive pulmonary disease (COPD) has led to enthusiastic investigation in search of novel muscarinic antagonists which share some of the beneficial characteristics of tiotropium and perhaps improve upon less desirable ones. Areas covered: Aclidinium bromide is a new muscarinic antagonist that has been developed to relieve… 
7 Citations
Muscarinic Receptor Antagonists.
Treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients and further beneficial effects of SAMAs and LAMAs are seen when added to existing treatments, including LABAs, inhaled corticosteroids and phosphodiesterase 4 inhibitors.
Chronic obstructive pulmonary disease b2-Agonists Antimuscarinic agents Methylxanthines Choice of bronchodilators Emerging bronchodilators
It is likely that an approach using muscarinic antagonist b2-agonist (MABA) molecules will provide the best opportunity to develop combinations that combine corticosteroids with 2 bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD.
Bronchodilators: current and future.
The muscarinic β2-agonist molecules approach likely provides the best opportunity to develop combinations that combine corticosteroids with dual-bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD.
AUTHOR PROOF COPY Not for publication
It is documented that ACLI/FORM, a twice- daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated.
High altitude pulmonary edema among “Amarnath Yatris”
Altitude sickness is common among Amaranath Yatris from the plains and appropriate educational strategies should be invoked for prevention and prompt treatment.
Forme cristalline et amorphe de chlorure d'aclidinium et procédé de préparation correspondant
L'invention concerne de nouvelles formes de chlorure d'aclidinium de formule I. Le procede de preparation de chlorure d'aclidinium cristallin consiste a mettre en reaction l'ester de quinuciidinyle
Respiratory Disorders, 4. Inhalants for Obstructive Airway Diseases (R03)


Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
Studies assessing the impact of aclidinium bromide/formoterol fumarate fixed-dose combination on COPD exacerbations, exercise capacity and hospitalisations are clearly needed to better detect its potential effects of disease modification in COPD.
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
Aclidinium is effective and well tolerated in patients with moderate to severe chronic obstructive pulmonary disease and time to first moderate or severe COPD exacerbation is significantly delayed in ACCLAIM/COPD II.
Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
Aclidinium bromide 100-900microg produced sustained bronchodilation over 24h in patients with COPD, and was undetected in plasma.
Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Aclidinium bromide exhibited time-independent PK following dosing to steady state, indicating that similar concentration versus time profiles will occur after repeated administration at the same dose and frequency.
Aclidinium bromide provides long-acting bronchodilation in patients with COPD.
Aclidinium 200microg was selected as the investigational dose for future clinical trials in COPD and was well tolerated, with no dose-dependent effect on ECG, laboratory parameters, or adverse events.
Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
  • M. Cazzola
  • Medicine
    Current opinion in investigational drugs
  • 2009
Clinical trials have demonstrated an unquestionably interesting pharmacological profile characterized by a faster rate of onset of the smooth muscle relaxing activity than tiotropium bromide and a rapid plasma hydrolysis in human plasma to inactive metabolites that may account for its favorable cardiovascular safety profile, but the disappointing efficacy results of the recent phase III trials have cast doubt on the real advantage of introducing this drug on the market.
Novel bronchodilators for the treatment of chronic obstructive pulmonary disease.
This review paper mainly focuses on recent results of preclinical studies that have used human tissue and clinical trials of new bronchodilators in patients with chronic obstructive pulmonary disease.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.
Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
In patients with COPD, aclidinium 400 μg bid compared with placebo provided clinically meaningful improvements in 24-h bronchodilation that generally were comparable to tiotropium 18 μg daily but with significant differences in favor of aclIDinium observed in the average nighttime period.
Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD
Aclidinium provided effective bronchodilation, similar to that seen with tiotropium, with significant improvements compared with placebo observed from 10 minutes post-dose, in patients with a post-bronchodilator forced expiratory volume in 1 second.